HOME >> MEDICINE >> NEWS
Standard treatment for lung cancer should be changed, say scientists

Copenhagen, Denmark: Patients with non-small cell lung cancer (NSCLC) are more likely to survive if they have chemotherapy after surgery than if they have surgery alone, said a scientist at ECCO 12 The European Cancer Conference in Copenhagen today (Tuesday 23 September). Dr. Bengt Bergman, of the Sahlgrenska University Hospital. Gteborg, Sweden, said that results from the International Adjuvant Lung Cancer Trial (IALT), which involved 1,867 patients in 33 countries, were sufficiently strong to recommend changing the standard treatment.

The randomised controlled trial showed an absolute 4.1% increase in survival after five years among those who had had adjuvant therapy with cisplatin, in combination with one of several other commonly-used cancer drugs. A 1995 meta-analysis of other trials showed a similar advantage for this therapy, but with only a borderline statistical significance since fewer patients with cisplatin treatment were included, said Dr. Bergman.

Recurrence of lung cancer was also reduced in the cisplatin arm of the trial. After 5 years 24% of those taking cisplatin had a local recurrence, whereas this occurred in 29% of the control arm. The study found no interaction between dose or treatment combination and survival benefit.

The trial was the first with sufficient numbers of patients to show a statistically significant survival benefit from adjuvant chemotherapy in NSCLC, said Dr. Bergman. "Although a 4.1% improvement may not seem very much on which to base recommending a change in treatment, it is in line with results from other common malignancies such as breast, ovarian, and colon cancer, where the survival gain from adjuvant chemotherapy lies in the range of 3.5 8%. In all these cases adjuvant treatment is now part of the routine treatment."

However, toxicity remains a problem, he said. "There are potentially serious side effects to this treatment, and we need better tools to identify the patients who are m
'"/>

Contact: Emma Mason
wordmason@aol.com
45-3252-4179
Federation of European Cancer Societies
23-Sep-2003


Page: 1 2

Related medicine news :

1. Standardizing disaster models to help first responders
2. Standardized blood pressure measurement could improve hypertension prevention, care in the Americas
3. Standard treatment for rare form of deafness no more effective than placebo
4. Standards of medical care on adventure holidays raise concerns
5. Mayo Clinic Study Finds Costs For Cancer Clinical Trials Comparable To Costs For Standard Treatment
6. Standardization Of Revolutionary Cancer Treatment Offers Hope To Patients Nationwide
7. Study Leads To New Standard Of Care For Treating Unstable Angina: Heart-Attack Risk Reduced By 47% With Use Of Tirofiban
8. Hormonal treatment improves survival in high-risk prostate cancer patients
9. Chronic pain treatments more effective when taken together, new study shows
10. Brain activity prior to treatment flags vulnerability to antidepressant side effects
11. Cultural and social factors influence prostate cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... ... 24, 2017 , ... In “Sky and I”, a young boy was walking home and feeling down about himself. ... him otherwise. The new friend says he can do whatever he wants to do if ... enough just the way he is. God created him with special talents and gifts. We ...
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... “The Gospel Truth Of The Bible: The ... “The Gospel Truth Of The Bible: The Other Sheep” is the creation of published author, ... born in the West Indies. He has been a member of the Seventh-day Adventist ...
(Date:9/23/2017)... ... September 23, 2017 , ... Silicon Valley Hair Institute, the leading ... new blog post focused on the ARTAS® hair transplant system and the younger demographic. ... the latest, most technologically sophisticated methods of hair restoration. , “It can be emotionally ...
(Date:9/22/2017)... ... ... MEDIA OPPORTUNITY: , Save Our Hospital - Albert Lea will host media ... against Mayo Clinic. Specifically, media can talk to steering committee members and patients regarding ... the Albert Lea hospital. , The rally aims to protect the most vulnerable and ...
(Date:9/22/2017)... PA (PRWEB) , ... September 22, 2017 , ... ... soon as possible, and they often saves lives. However, if one isn’t accessible ... to widen the availability of defibrillation, I came up with this idea," said ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
Breaking Medicine Technology:
Cached News: